X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:
Tuesday, November 10, 2020

Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock

MENLO PARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its previously announced underwritten public offering of an aggregate of 7,400,460 shares of its common stock at a price to the public of $14.25 per share. Pacific Biosciences is offering 6,096,112 shares of its common stock in the offering, and the selling stockholder is offering 1,304,348 shares of the Company’s common stock in the offering. The offering is expected to close on or about November 13, 2020 subject to satisfaction of customary closing…

Read More »

Tuesday, November 10, 2020

Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock

MENLO PARK, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced that it intends to offer and sell $85.0 million of shares of its common stock and a selling stockholder intends to offer 1,304,348 of common stock shares in an underwritten public offering. Pacific Biosciences also intends to grant the underwriters a 30-day option to purchase up to an additional $12.75 million of shares of its common stock, and the selling stockholder also intends to grant the underwriters a 30-day option to purchase up to an additional 195,652 shares of its common stock,…

Read More »

Monday, November 2, 2020

Pacific Biosciences of California, Inc. Announces Third Quarter 2020 Financial Results

MENLO PARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2020. Third Quarter 2020 Financial Results Total revenue for the third quarter of 2020 was $19.1 million, compared with $21.9 million for the same period of 2019. Instrument revenue for the third quarter of 2020 was $7.7 million, compared with $11.6 million for the same period of 2019. Consumables revenue for the third quarter of 2020 was $8.0 million compared with $6.9 million for the same period of 2019. Service and other revenue…

Read More »

Thursday, October 22, 2020

Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics

SAN FRANCISCO and MENLO PARK, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) — Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a research collaboration focused on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. To support this collaboration, Invitae is expanding their PacBio sequencing capacity to meet the growing demand for clinical applications dependent on highly accurate genomic information. More than half of epilepsies can be traced to a genetic cause.…

Read More »

Monday, October 19, 2020

Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call

MENLO PARK, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2020 Financial Results on Monday, November 2, 2020, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences’ website at: https://investor.pacificbiosciences.com/. Date: November 2, 2020 Time: 4:30pm ET Listen via Internet: https://investor.pacificbiosciences.com/ Toll-free: 888.366.7247 International: 707.287.9330 Conference ID: 5173038 Replay: https://investor.pacificbiosciences.com About Pacific Biosciences Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on…

Read More »

Thursday, October 15, 2020

Children’s Mercy Kansas City Teams Up with Pacific Biosciences to Fight Rare Disease

Collaboration will utilize PacBio’s highly accurate HiFi sequencing to solve rare pediatric genetic diseases that have proven intractable in previous studies KANSAS CITY, Mo., and MENLO PARK, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) — Children’s Mercy Kansas City, one of the nation’s top pediatric medical systems, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a collaboration designed to further understand the most challenging pediatric diseases. The organizations will team up to sequence a statistically significant cohort of rare disease cases for which previous whole-genome and whole-exome sequencing studies…

Read More »

Monday, October 5, 2020

Pacific Biosciences Launches the Sequel IIe System to Accelerate Adoption of Highly Accurate HiFi Sequencing

New system features advanced on-instrument data processing and cloud enablement to deliver HiFi data faster and with significant reduction in compute and data storage costs MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced the launch of the Sequel® IIe System, the next instrument evolution based on the company’s Single Molecule, Real-Time (SMRT®) Sequencing technology. With increased computational capacity and on-instrument data processing, the new system can directly produce highly accurate long reads (HiFi reads) more quickly and more cost-effectively than ever,…

Read More »

Monday, September 14, 2020

Pacific Biosciences Announces New Chief Financial Officer

MENLO PARK, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced the appointment of Susan G. Kim as Chief Financial Officer, effective as of September 28, 2020. “I am delighted that Susan is joining the company at a time where we have many opportunities to drive growth,” said Christian Henry, recently appointed Chief Executive Officer of Pacific Biosciences.  “Susan’s deep experience in all aspects of financial operations will help drive our execution. Susan is also a highly capable leader who has managed…

Read More »

Tuesday, August 11, 2020

Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock

MENLO PARK, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its previously announced underwritten public offering of 19,430,000 shares of its common stock at a price to the public of $4.47 per share.  The offering is expected to close on or about August 14, 2020 subject to satisfaction of customary closing conditions.  Pacific Biosciences also granted the underwriters a 30-day option to purchase up to an additional 2,914,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. …

Read More »

Tuesday, August 11, 2020

Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock

MENLO PARK, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced that it intends to offer and sell $75.0 million of shares of its common stock in an underwritten public offering.  Pacific Biosciences also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.  The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as…

Read More »

Friday, August 7, 2020

Pacific Biosciences Announces New Chief Executive Officer

Christian O. Henry Named Chief Executive Officer John F. Milligan, Ph.D. Named Chairman of the Board Ben Gong Named Interim CFO MENLO PARK, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced the appointment of Christian O. Henry as President and Chief Executive Officer, effective as of September 14,  2020. Mr. Henry has served on our Board of Directors since 2018, including as Chairman of the Board since March 2020. Dr. John F. Milligan, a Board member since 2013, has been appointed…

Read More »

Monday, August 3, 2020

Pacific Biosciences of California, Inc. Announces Second Quarter 2020 Financial Results

MENLO PARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2020. Total revenue for the second quarter of 2020 was $17.1 million, compared with $24.6 million for the same period of 2019. Instrument revenue for the second quarter of 2020 was $8.9 million, compared with $12.7 million for the same period of 2019. Consumables revenue for the second quarter of 2020 was $4.8 million compared with $8.6 million for the same period of 2019. Service and other revenue for the second quarter of…

Read More »

Monday, August 3, 2020

Pacific Biosciences and Asuragen Collaborate to Develop Assays for Carrier Screening and other Applications Based on SMRT Sequencing Technology and AmplideX PCR Chemistry

Joint research effort will lead to molecular assays that can improve variant detection and access difficult-to-sequence regions of the human genome AUSTIN, Texas and MENLO PARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, and Asuragen, a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, today announced their clinical research collaboration aimed at developing molecular assays based on PacBio’s Single Molecule, Real-Time (SMRT®) Sequencing technology. The initial focus of the collaboration will be on research in support of assay development…

Read More »

Friday, July 24, 2020

Pacific Biosciences of California, Inc. Second Quarter 2020 Financial Results Call

MENLO PARK, Calif., July 24, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Second Quarter 2020 Financial Results on Monday, August 3, 2020, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences’ website at:  https://investor.pacificbiosciences.com/. Date:  August 3, 2020 Time:  4:30pm ET Listen via Internet:  https://investor.pacificbiosciences.com/ Toll-free:  888.366.7247 International:  707.287.9330 Conference ID: 7079947 Replay:  https://investor.pacificbiosciences.com About Pacific Biosciences Pacific Biosciences of California, Inc. (NASDAQ:PACB), is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®)…

Read More »

Wednesday, June 10, 2020

Pacific Biosciences Announces Planned Retirement of CEO, Dr. Michael Hunkapiller

Dr. Hunkapiller to retire by the end of 2020 Susan K. Barnes, CFO to retire in August 2020 MENLO PARK, Calif., June 10, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Hunkapiller, Ph.D. is retiring as Chief Executive Officer and President by the end of the year.  Dr. Hunkapiller plans to remain on the Board of Directors.  The company also announced that Susan K. Barnes plans to retire and will be leaving the company in August 2020.  Ms. Barnes will continue in…

Read More »

1 2 3 15

Subscribe for blog updates:

Archives